Anti-CTSS / Cathepsin S (Fsn0503h) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma. MW :144.28 KD.

Anti-CTSS / Cathepsin S (Fsn0503h) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma. MW :144.28 KD.

Anti-CXADR is a monoclonal antibody (MAb) targeting CXADR/CAR. It exhibits anti-cancer activity. MW :150 KD.

Anti-CXADR is a monoclonal antibody (MAb) targeting CXADR/CAR. It exhibits anti-cancer activity. MW :150 KD.

Anti-CXADR is a monoclonal antibody (MAb) targeting CXADR/CAR. It exhibits anti-cancer activity. MW :150 KD.

Anti-CXC-ELR is a monoclonal antibody that binds to an ELR+ CXC chemokine and inhibits its biological activity. MW: 146.56 KD.

Anti-CXC-ELR is a monoclonal antibody that binds to an ELR+ CXC chemokine and inhibits its biological activity. MW: 146.56 KD.

Anti-CXC-ELR is a monoclonal antibody that binds to an ELR+ CXC chemokine and inhibits its biological activity. MW: 146.56 KD.

Anti-CXCL10 / IP-10 (NI-0801) is a fully human monoclonal antibody against chemokine (C-X-C motif) ligand 10 (CXCL10). It has the potential to treat primary biliary cholangitis. MW: 146.08.

Anti-CXCL10 / IP-10 (NI-0801) is a fully human monoclonal antibody against chemokine (C-X-C motif) ligand 10 (CXCL10). It has the potential to treat primary biliary cholangitis. MW: 146.08.

Anti-CXCL10 / IP-10 (NI-0801) is a fully human monoclonal antibody against chemokine (C-X-C motif) ligand 10 (CXCL10). It has the potential to treat primary biliary cholangitis. MW: 146.08.

Anti-CXCL12 / SDF1a (Genentech anti-CXCL12) is a humanized monoclonal antibody (mAb) against CXCL12 (stromal-derived factor 1 (SDF1)) with anti-tumor activity. MW: 145.12.

Anti-CXCL12 / SDF1a (Genentech anti-CXCL12) is a humanized monoclonal antibody (mAb) against CXCL12 (stromal-derived factor 1 (SDF1)) with anti-tumor activity. MW: 145.12.

Anti-CXCL12 / SDF1a (Genentech anti-CXCL12) is a humanized monoclonal antibody (mAb) against CXCL12 (stromal-derived factor 1 (SDF1)) with anti-tumor activity. MW: 145.12.

Anti-CXCL4 / PF4 is a monoclonal antibody against anti-CXC chemokine ligand 4 (CXCL4, also called PF4). MW: 144.86 KD.

Anti-CXCL4 / PF4 is a monoclonal antibody against anti-CXC chemokine ligand 4 (CXCL4, also called PF4). MW: 144.86 KD.

Anti-CXCL4 / PF4 is a monoclonal antibody against anti-CXC chemokine ligand 4 (CXCL4, also called PF4). MW: 144.86 KD.

Anti-CXCL8 / IL-8 (ABX-IL8) is a antibody targeting CXCL8. MW: 145.5 KD.

Anti-CXCL8 / IL-8 (ABX-IL8) is a antibody targeting CXCL8. MW: 145.5 KD.

Anti-CXCL8 / IL-8 (ABX-IL8) is a antibody targeting CXCL8. MW: 145.5 KD.

Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has strong antitumor effect. MW :144.94 KD.

Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has strong antitumor effect. MW :144.94 KD.

Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has strong antitumor effect. MW :144.94 KD.

Anti-CXCL9 is an antibody targeting CXCL9 chemokine. It has the potemtial of inhibiting inflammation. MW :150 KD.

Anti-CXCL9 is an antibody targeting CXCL9 chemokine. It has the potemtial of inhibiting inflammation. MW :150 KD.

Anti-CXCL9 is an antibody targeting CXCL9 chemokine. It has the potemtial of inhibiting inflammation. MW :150 KD.

Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.

Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.

Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD.

Anti-CXCR5 / CD185 (SAR113244) is a humanized monoclonal antibody that specifically targets CXCR5. It can be used in the treatment of arthritis, autoimmune diseases, inflammatory diseases, graft rejection, and cancer . MW :144.1 KD.

Anti-CXCR5 / CD185 (SAR113244) is a humanized monoclonal antibody that specifically targets CXCR5. It can be used in the treatment of arthritis, autoimmune diseases, inflammatory diseases, graft rejection, and cancer . MW :144.1 KD.

Anti-CXCR5 / CD185 (SAR113244) is a humanized monoclonal antibody that specifically targets CXCR5. It can be used in the treatment of arthritis, autoimmune diseases, inflammatory diseases, graft rejection, and cancer . MW :144.1 KD.

Anti-CYR61 / CCN1 is a monoclonal antibody targeting cysteine-rich protein 61(CCN1/Cyr61) . It can be used in breast cancer treatment. MW :144.42 KD.

Anti-CYR61 / CCN1 is a monoclonal antibody targeting cysteine-rich protein 61(CCN1/Cyr61) . It can be used in breast cancer treatment. MW :144.42 KD.

Anti-CYR61 / CCN1 is a monoclonal antibody targeting cysteine-rich protein 61(CCN1/Cyr61) . It can be used in breast cancer treatment. MW :144.42 KD.

Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.

Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.

Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD.

Anti-DCBLD2 / ESDN (FA19-1) is a polyclonal antibody that targets the DCBLD2. It inhibits tumor metastasis in lung adenocarcinoma (LUAD). MW :146.84 KD.

Anti-DCBLD2 / ESDN (FA19-1) is a polyclonal antibody that targets the DCBLD2. It inhibits tumor metastasis in lung adenocarcinoma (LUAD). MW :146.84 KD.

Anti-DCBLD2 / ESDN (FA19-1) is a polyclonal antibody that targets the DCBLD2. It inhibits tumor metastasis in lung adenocarcinoma (LUAD). MW :146.84 KD.

Anti-DCSTAMP is an antibody targeting Dendritic cell-specific transmembrane protein, DC-STAMP. It is essential for cell-to-cell fusion to form multinucleated osteoclasts (OCs) during osteoclastogenesis. MW :146.2 KD.

Anti-DCSTAMP is an antibody targeting Dendritic cell-specific transmembrane protein, DC-STAMP. It is essential for cell-to-cell fusion to form multinucleated osteoclasts (OCs) during osteoclastogenesis. MW :146.2 KD.

Anti-DCSTAMP is an antibody targeting Dendritic cell-specific transmembrane protein, DC-STAMP. It is essential for cell-to-cell fusion to form multinucleated osteoclasts (OCs) during osteoclastogenesis. MW :146.2 KD.

Anti-DDR1 / CD167a (Imperial College anti-DDR1) is a monoclonal antibody againts discoidin domain receptor 1 with potential anti-tumor activity. MW: 143.32 KD.

Anti-DDR1 / CD167a (Imperial College anti-DDR1) is a monoclonal antibody againts discoidin domain receptor 1 with potential anti-tumor activity. MW: 143.32 KD.

Anti-DDR1 / CD167a (Imperial College anti-DDR1) is a monoclonal antibody againts discoidin domain receptor 1 with potential anti-tumor activity. MW: 143.32 KD.

Anti-DKK1 (BHQ880) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease.